Welch Group LLC purchased a new stake in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 58,700 shares of the company's stock, valued at approximately $101,000.

Other hedge funds have also recently made changes to their positions in the company. Sugarloaf Wealth Management LLC acquired a new stake in shares of Alaunos Therapeutics during the third quarter valued at about $136,000. Commerce Bank bought a new position in shares of Alaunos Therapeutics during the second quarter worth about $569,000. CIBC Private Wealth Group LLC bought a new position in shares of Alaunos Therapeutics during the second quarter worth about $51,000. Kettle Hill Capital Management LLC bought a new position in shares of Alaunos Therapeutics during the second quarter worth about $427,000. Finally, Gamble Jones Investment Counsel bought a new position in shares of Alaunos Therapeutics during the second quarter worth about $76,000. 33.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Wells Fargo & Company restated an "overweight" rating and set a $3.00 price objective on shares of Alaunos Therapeutics in a research report on Tuesday, October 4th.

Alaunos Therapeutics Price Performance

Alaunos Therapeutics (NASDAQ:TCRT – Get Rating) last issued its earnings results on Monday, November 14th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.08. The business had revenue of $2.91 million during the quarter. As a group, sell-side analysts anticipate that Alaunos Therapeutics, Inc. will post -0.16 EPS for the current year.

Insiders Place Their Bets

In other Alaunos Therapeutics news, Director Robert W. Postma bought 750,000 shares of the stock in a transaction on Tuesday, November 29th. The stock was acquired at an average cost of $0.65 per share, for a total transaction of $487,500.00. Following the completion of the acquisition, the director now owns 5,000,000 shares in the company, valued at approximately $3,250,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.90% of the stock is currently owned by corporate insiders.

About Alaunos Therapeutics

(Get Rating)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.

Featured Articles

• Get a free copy of the StockNews.com research report on Alaunos Therapeutics (TCRT)
• Will Tesla Shares Rally If Musk Steps Down From Twitter?
• 5 Down But Not Out Stocks To Watch For 2023
• Can Chewy Fetch Double Digit Gains in 2023?
• Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
• Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why

Want to see what other hedge funds are holding TCRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating).

Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.